A California-based venture capital firm was founded in 2014 by a parent company based in China. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K, and hopes to invest more capital in later rounds (i.e. Series A to B) as follow on investments to portfolio companies. The firm seeks investment opportunities globally.
The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.
The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A venture capital firm with offices worldwide closed a $500M fund in 2016. The firm invests mainly in early-stage technology companies (i.e. internet, SaaS, consumer-tech, etc.) with high disruptive potential and seeks to be the first institutional investor, but dedicates a small amount of capital (about 20% of the fund) to later-stage companies as well. Typically, first checks fall in the $2-5M range in Seed to Series A rounds, but the firm has made investments as small as $250K. Overall, the firm invests in over 20 companies per year across North America and Asia. In terms of healthtech specifically, the firm makes 1-2 USA-based and 1 China-based investments per year.
In the healthcare sector, the firm is mainly interested in healthcare IT opportunities and will not consider therapeutics or medical devices. The firm will stray away from anything that involves FDA regulatory approval. Previous investments of the firm have included tools to improve physician workflow, healthcare AI applications, and wearable health trackers for a consumer market. Companies do not need to be generating revenue prior to investment.
The firm invests in private companies with strong technology and can work with different kinds of management teams that are ideally devoted full-time to the company. The firm will almost always act as the lead investor and seek board representation, staying actively involved in their portfolio companies. The firm prefers to have a syndicate of co-investors invest alongside the firm, but this is not an absolute requirement.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
A venture capital firm based in Europe with an additional office in New York manages €176 million in total assets across two funds. The firm typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€8million ($0.7million-$10million). The current fund aims to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.
The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.
The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
LSN is pleased to announce WuXi AppTec will be a title sponsor to the RESI Conference Series in our upcoming Boston, NYC and San Francisco conferences. WuXi AppTec is a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform. WuXi AppTec joins RESI as a title sponsor along with JLABS, which currently has eight locations in innovation hotspots across North America and produces entrepreneurial programs and campaigns to seek out the best science. This pair of global early stage players will add another conduit to the early stage companies that come to RESI to find investor capital and strategic partnerships as they move forward in their product cycles.
The WuXi AppTec-LSN relationship has been growing over the years and WuXi AppTec has helped and been a contributor in our efforts with RESI content programing, panel participation, and creation of relationships with the scientist entrepreneurs and fundraising CEOs who are the main constituents of the RESI conference series.
By Chris Cummings, Senior Business Development Manager, LSN
With just over seven weeks to go RESI Boston, LSN is getting ready to assess which health innovators will be awarded a display spot in our NIH-sponsored RESI Innovation Challenge. If you would like to participate and get an exhibit hall display spot to market your company to life science investors, it’s not too late to apply.
The RESI Innovation Challenge covers startups in therapeutics, medtech, diagnostics and healthcare IT companies from around the globe. All applicants will be vetted based on not only the quality of the company’s scientific work, but also the strength of the management team and how well-positioned the company is to receive investment.
On September 26th, RESI’s estimated 1000 attendees will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership. See below for the previous RESI Innovation Challenge first place winners – a diverse group of startups from every area of the life sciences.
Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera
See below for the previous RESI Innovation Challenge testimonials.
“RESI Innovation Challenge was a fantastic way for us to increase exposure to investors attending the event. We highly recommend leveraging the Innovation Challenge with the one-on-one partnering platform to get more face time with investors.”
– Herman Lo, CEO, ViewsIQ Inc.
3rd Place in San Diego IC
“It was an absolute pleasure to participate in the RESI conference held at MaRS in Toronto. The unique structure of the conference facilitated creating new relationships with potential investors and partners. In particular, the Innovation Challenge pushed us to introduce ourselves to new people, which will be useful as we look towards a future financing round. I definitely recommend the RESI conferences to entrepreneurs seeking financing in the bio / health space.”
– Raymond Shih, President, Co-Founder, QoC Health
3rd Place, RESI on MaRS, June 23, 2016
“The RESI Innovation Challenge is a really good opportunity to meet investors and other companies in the space. It’s a good showcase to reach that audience.”
– Jessica Ching, CEO, Eve Medical
2nd Place, RESI San Francisco, January 12, 2016
“The RESI Innovation Challenge is a unique way to pitch, and provides a great opportunity to see what other companies are doing in the industry, while allowing you to meet with potential investors and strategic partners outside of the partnering meetings.”
– John Connolly, VP Corporate Development, Rna Diagnostics
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
For the week of September 25-29th things will be jumpin’ in the city of Boston! Life Science Nation’s Redefining Early Stage Investments (RESI) Conference takes place on Tuesday September 26th, and several other events are coming to the city as well. So if you are attending RESI Boston, please peruse our list of recommended hotels and get a room booked ASAP.
It is eminently clear to me that Boston will be fully occupied that week. If you are a scientist entrepreneur or a fundraising CEO, check out the early stage investors and strategic partners already signed up to attend RESI. As a born and raised Bostonian, I implore you to not wait any longer – you can get signed up for RESI Boston right here. And once you’ve signed up, save yourself the aggravation and book a room early. The one thing you don’t want when attending a conference in Boston is a tedious commute from outside of city – it can be a challenge even for the well-worn road warriors of life science.
The corporate venture / life science investment arm of a life science and medical equipment manufacturer invests from an evergreen fund. The firm prefers to invest at company formation / seed stage, but no later than Series A. Typical investments range from USD1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.
The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these sectors.
The firm prefers to invest in teams with a strong track record, but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of its parent company to help companies with regulatory affairs, market access and distribution, especially in the life sciences tools and fertility markets.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
